CED recently spoke with Steve McCoy, Head of Sales for LabVoice, to explore what makes their technology so vital to scientists in their lab workflows. What does LabVoice do? LabVoice gives scientists a hands-free laboratory experience by bringing the first voice assistant tailored specifically to users and their laboratories. We know that scientists want to […]
Author: CED NC
Gemelli Biotech: Revolutionizing Testing with trio-smartā¢
After the launch of their novel breath test, trio-smartā¢, earlier this month, CED caught up with Gemelli Biotech CEO Matt Mitcho. Learn more about what makes this new product revolutionary for many and how he was introduced to the CED network. How did you get involved with CED and what benefits have you seen from […]
Finexio: Adversity, Flexibility, Persistence & Humility
CED recently spoke with Ernest Rolfson, CEO and Founder of Finexio, to learn more about how Finexio is disrupting the relationship between corporates and their bank. Read more and be sure to introduce yourself at the next CED event!
CED Kicks-Off the first GRO Incubator.
This week marks the beginning of CEDās newest entrepreneurial education program, GRO Incubator, building on an almost 40-year history of educating and connecting entrepreneurial companies with high-value resources to accelerate business growth. Through their program, CED leverages their expansive network to provide specialized coaching and support. “For all these years, the secret sauce of CED […]
Celebrating Innovation and Progress within our Ecosystem.
CED had a chance to catch up with Deshawn, who you may have seen pitch at Venture Connect Online back in May. Deshawn is a NCSU Graduate and a TechStars backed Founder who is continuing to make progress with his platform both locally and internationally.
CED Partner, Plakous Therapeutics joins forces with Mayo Clinic to embark on a natural history study to support their work developing a life-saving drug for children.
CED Partner, Plakous Therapeutics joins forces with Mayo Clinic to embark on a natural history study to support their work developing a life-saving drug for children. Rob Boyce, CEO of Plakous Therapeutics, is making considerable progress to drive solutions for Necrotizing Enterocolitis (NEC), a rare disease affecting the worldās youngest patients – premature babies.